Please, update your browser to view this website correctly. Update my browser now
Recent study on Alport syndrome highlight the critical role of precision medicine in personalizing treatment according to each patient’s genetic profile. Advances in genetic research and bioengineering innovation are increasingly converging to enable ultra-specialized management of patients with kidney disease from the very first days of life.
The ability to identify aggressive genetic variants at an early stage allows clinicians to stratify risk and plan the use of advanced, miniaturized dialysis technologies well before the patient reaches end-stage kidney disease, optimizing timing and preparation for potential inclusion on the transplant waiting list.
A deeper understanding of the molecular mechanisms governing the function of the glomerular filtration barrier and the preservation of its structural integrity provides powerful tools for testing targeted therapies capable of preventing structural renal collapse and clarifying the mechanisms underlying disease progression.
This meeting brings together the International Renal Research Institute of Vicenza (IRRIV) and the European Renal Association (ERA) to foster collaboration and share advances in research and patient care in Alport syndrome and related hereditary kidney disorders.
The program will provide an opportunity to examine key updates from the latest Alport syndrome guidelines, explore emerging glomerulus-on-a-chip technology, and discuss miniaturized dialysis systems such as CARPEDIEM (Cardio-Renal Pediatric Dialysis Emergency Machine), which enable renal replacement therapy in neonates and infants with very low body weight (under 10 kg).
A roundtable with expert specialists will foster open discussion, mutual enrichment, and constructive professional exchange.
CERTIFICATE
Each participant will be sent a certificate of attendance.
ENDORSEMENTS
